

Clinical course of high-risk patients diagnosed with an

Journal of Thrombosis and Haemostasis

8, 237-242

DOI: [10.1111/j.1538-7836.2009.03674.x](https://doi.org/10.1111/j.1538-7836.2009.03674.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. <i>Advances in Hematology</i> , 2009, 2009, 1-5.	1.0	14
3	The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours?. <i>Autoimmunity Highlights</i> , 2010, 1, 5-14.	3.9	15
4	The "antiphospholipid triangle" in an asymptomatic patient: a case report. <i>Internal and Emergency Medicine</i> , 2010, 5, 457-458.	2.0	1
5	The antiphospholipid triangle. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 234-236.	3.8	21
6	Retinal vein thrombosis: pathogenesis and management. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1886-1894.	3.8	175
7	New therapeutic targets for the antiphospholipid syndrome. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1291-1299.	3.4	11
8	Challenges in the Diagnosis of the Antiphospholipid Syndrome. <i>Clinical Chemistry</i> , 2010, 56, 930-940.	3.2	74
9	Antiphospholipid syndrome. <i>Lancet, The</i> , 2010, 376, 1498-1509.	13.7	916
10	Acquired and Inherited Thrombophilia Disorders in Pregnancy. <i>Obstetrics and Gynecology Clinics of North America</i> , 2011, 38, 271-295.	1.9	21
11	"Criteria"™ aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. <i>Lupus</i> , 2011, 20, 182-190.	1.6	122
12	Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. <i>Lupus</i> , 2011, 20, 206-218.	1.6	467
13	Antiphospholipid syndrome: Unusual clinical presentations. <i>Thrombosis Research</i> , 2011, 127, S47-S50.	1.7	6
14	APS " controversies in diagnosis and management, critical overview of current guidelines. <i>Thrombosis Research</i> , 2011, 127, S51-S52.	1.7	22
16	Laboratory Testing for Antiphospholipid Syndrome. , 2011, , 985-1000.		0
18	Diagnostic test combinations associated with thrombosis in lupus anticoagulant positive patients. <i>Thrombosis and Haemostasis</i> , 2011, 105, 736-738.	3.4	21
19	Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. <i>Blood</i> , 2011, 118, 4714-4718.	1.4	404
20	Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. <i>Journal of Internal Medicine</i> , 2011, 270, 110-122.	6.0	91
21	Antiphospholipid syndrome: interpretation of laboratory data. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 402-403.	3.8	14

#	ARTICLE	IF	CITATIONS
22	False-negative or false-positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1435-1436.	3.8	8
23	Primary Thrombosis Prophylaxis in Antiphospholipid Antibody-Positive Patients: Where Do We Stand?. <i>Current Rheumatology Reports</i> , 2011, 13, 59-69.	4.7	66
24	Acquired immune-mediated thrombophilia in lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2011, 52, 1836-1843.	1.3	22
26	Antiphospholipid Syndrome Clinical Research Task Force Report. <i>Lupus</i> , 2011, 20, 219-224.	1.6	36
27	Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It. <i>Scientifica</i> , 2012, 2012, 1-17.	1.7	27
28	Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): demographic features, risk factors, clinical and laboratory profile. <i>Lupus</i> , 2012, 21, 806-809.	1.6	32
29	Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2012, 24, 473-481.	4.3	30
30	Interpretation of laboratory data and need for reference laboratories. <i>Lupus</i> , 2012, 21, 732-733.	1.6	9
31	The Future of Antiphospholipid Antibody Testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 412-420.	2.7	23
32	Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 339-347.	2.7	35
33	Prevalence of Annexin A5 Resistance in Children and Adolescents with Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2012, 39, 382-388.	2.0	4
34	Interpretation and Recommended Testing for Antiphospholipid Antibodies. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 348-352.	2.7	23
35	Current International Initiatives in Antiphospholipid Antibody Testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 360-374.	2.7	24
36	The Michael Mason prize: Pathogenic antiphospholipid antibodies, stressed out antigens and the deployment of decoys. <i>Rheumatology</i> , 2012, 51, 32-36.	1.9	8
37	Secondary prevention in thrombotic antiphospholipid syndrome. <i>Lupus</i> , 2012, 21, 734-735.	1.6	10
38	ECAT veritas?. <i>Lupus</i> , 2012, 21, 722-724.	1.6	18
39	Detection of anticardiolipin antibody IgG by time-resolved fluoroimmunoassay. <i>Clinical Rheumatology</i> , 2012, 31, 1339-1345.	2.2	4
41	Antiphospholipid syndrome: Diagnosis. <i>Revue De Medecine Interne</i> , 2012, 33, A5-A6.	1.0	0

#	ARTICLE	IF	CITATIONS
43	Antiphospholipid antibodies and thrombosis. <i>Thrombosis Research</i> , 2012, 129, 345-347.	1.7	6
44	Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists. <i>Thrombosis Research</i> , 2012, 129, e168-e170.	1.7	11
45	Antiphospholipid antibodies: Evaluation of the thrombotic risk. <i>Thrombosis Research</i> , 2012, 130, S37-S40.	1.7	48
46	Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2512-2518.	3.8	96
47	ISTH guidelines on Lupus Anticoagulant testing. <i>Thrombosis Research</i> , 2012, 130, S76-S77.	1.7	34
48	Recurrent Miscarriage, Antiphospholipid Antibodies and the Risk of Thromboembolic Disease. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 43, 265-274.	6.5	23
49	22 Erworbene Thrombophilie. , 2012, , .		0
50	31 Diagnostik der Antiphospholipid-Antikörper (aPL). , 2012, , .		0
51	Epidemiology of recurrent venous thrombosis. <i>Brazilian Journal of Medical and Biological Research</i> , 2012, 45, 1-7.	1.5	13
52	Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "Pros" and "Cons". <i>Autoimmunity Reviews</i> , 2012, 11, 568-571.	5.8	22
53	High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: "PROS"™ and "CONS"™. <i>Autoimmunity Reviews</i> , 2012, 11, 577-580.	5.8	38
54	Antiphospholipid antibody testing - slow progress?. <i>International Journal of Clinical Practice</i> , 2012, 66, 533-535.	1.7	3
55	Guidelines on the investigation and management of antiphospholipid syndrome. <i>British Journal of Haematology</i> , 2012, 157, 47-58.	2.5	492
56	Clinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations. <i>Internal Medicine Journal</i> , 2012, 42, 427-434.	0.8	12
57	Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. <i>Arthritis and Rheumatism</i> , 2012, 64, 504-512.	6.7	227
59	Maladies rares en médecine d'urgence. <i>Références En Médecine D'urgence</i> , 2013, , .	0.0	0
60	Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. <i>Immunologic Research</i> , 2013, 56, 358-361.	2.9	48
61	Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. <i>Immunologic Research</i> , 2013, 56, 432-438.	2.9	57

#	ARTICLE	IF	CITATIONS
62	Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thromboses in patients with the antiphospholipid syndrome. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2013, 7, 1-15.	0.4	5
63	Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1927-1929.	3.8	112
65	Identification of the binding site for fondaparinux on Beta2-glycoprotein I. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2013, 1834, 2080-2088.	2.3	7
66	Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. <i>Rheumatology</i> , 2013, 52, 501-509.	1.9	44
67	The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 659-668.	3.0	5
69	Artériopathies non athéromateuses : quels conseils donner aux cardiologues ?. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2013, 2013, 16-21.	0.0	0
70	Thrombotic recurrences and bleeding events in APS vascular patients: A review from the literature and a comparison with the APS Piedmont Cohort. <i>Autoimmunity Reviews</i> , 2013, 12, 826-831.	5.8	25
71	Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry. <i>British Journal of Haematology</i> , 2013, 163, 655-665.	2.5	55
72	Guidelines for the treatment of antiphospholipid syndrome. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 184-192.	0.7	9
73	Anticardiolipin Antibody and Anti-beta 2 Glycoprotein I Antibody Assays. <i>Methods in Molecular Biology</i> , 2013, 992, 387-405.	0.9	9
74	Antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 675-680.	2.5	77
75	Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1527-1531.	3.8	94
76	Diagnosis of antiphospholipid syndrome in routine clinical practice. <i>Lupus</i> , 2013, 22, 18-25.	1.6	112
78	Measurement of Lupus Anticoagulants: An Update on Quality in Laboratory Testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 267-271.	2.7	21
79	High Prevalence of Prothrombotic Abnormalities in Multifocal Osteonecrosis. <i>Medicine (United States)</i> , 2013, 92, 1075-1080.	1.0	27
80	Syndrôme des antiphospholipides. <i>Recherches En Médecine D'urgence</i> , 2013, , 241-259.	0.0	0
81	Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. <i>European Respiratory Journal</i> , 2013, 41, 462-468.	6.7	361
82	Thromboembolism risk following recurrent miscarriage. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1503-1513.	1.5	2

#	ARTICLE	IF	CITATIONS
83	The lupus anticoagulant: results from 2257 patients attending a high-risk pregnancy clinic. <i>Blood</i> , 2013, 122, 341-347.	1.4	37
84	Trends in the Antiphospholipid Syndrome Criteria. <i>Journal of Hematology & Thromboembolic Diseases</i> , 2013, 01, .	0.1	0
85	Thrombotic Risk in the Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 741-746.	2.7	21
86	Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety. <i>ISRN Rheumatology</i> , 2014, 2014, 1-13.	1.9	7
87	Leg ulcers in antiphospholipid syndrome secondary to systemic lupus erythematosus treated with intravenous immunoglobulin. <i>Journal of Dermatological Case Reports</i> , 2014, 8, 38-41.	1.1	2
88	The Paradox of the Lupus Anticoagulant: History and Perspectives. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 860-865.	2.7	13
89	Antiphospholipid antibody testing for the antiphospholipid syndrome: a comprehensive practical review including a synopsis of challenges and recent guidelines. <i>Pathology</i> , 2014, 46, 481-495.	0.6	58
90	Clinical performance of anticardiolipin and anti β 2 glycoprotein I antibodies using a new automated chemiluminescent assay. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 10-15.	1.0	16
91	Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome. <i>Thrombosis Research</i> , 2014, 133, 936-944.	1.7	23
92	Treatment of the antiphospholipid syndrome. <i>Autoimmunity Highlights</i> , 2014, 5, 1-7.	3.9	17
93	Management of Recurrent Thrombosis in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2014, 16, 405.	4.7	33
95	A novel ELISA system for simultaneous detection of six subclasses of anti-phospholipid antibodies for prediction of thrombotic complications among SLE patients. <i>Thrombosis Research</i> , 2014, 133, 1135-1140.	1.7	11
96	The chequered history of the antiphospholipid syndrome. <i>British Journal of Haematology</i> , 2014, 165, 609-617.	2.5	21
97	Antiphospholipid antibody syndrome. <i>Clinical Queries Nephrology</i> , 2014, 3, 9-14.	0.2	0
98	New oral anticoagulants in thrombotic antiphospholipid syndrome. <i>Lupus</i> , 2014, 23, 1279-1282.	1.6	34
99	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). <i>Rheumatology</i> , 2014, 53, 275-284.	1.9	71
100	Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation. <i>Lupus</i> , 2014, 23, 1252-1254.	1.6	24
101	The relationship between mean platelet volume and thrombosis recurrence in patients diagnosed with antiphospholipid syndrome. <i>Rheumatology International</i> , 2014, 34, 1599-1605.	3.0	26

#	ARTICLE	IF	CITATIONS
102	An update on current management strategies for antiphospholipid syndrome-related thrombosis. <i>Clinical Lipidology</i> , 2014, 9, 91-100.	0.4	2
103	Antibodies to phosphatidylserine/prothrombin complex and the antiphospholipid syndrome. <i>Lupus</i> , 2014, 23, 1309-1312.	1.6	18
104	Neurologic Manifestations of Hematologic Disorders. , 2014, , 505-537.		0
105	Testing for Antiphospholipid antibodies with Solid Phase Assays: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 792-795.	3.8	175
106	Current treatment strategies for management of antiphospholipid syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 205-215.	0.8	0
107	Antithrombotic treatment for stroke associated with antiphospholipid antibodies. <i>Expert Review of Hematology</i> , 2014, 7, 169-172.	2.2	6
108	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Autoimmunity Reviews</i> , 2014, 13, 917-930.	5.8	224
109	Inhibition of thrombotic properties of persistent autoimmune anti- β 2GPI antibodies in the mouse model of antiphospholipid syndrome. <i>Blood</i> , 2014, 123, 1090-1097.	1.4	35
110	Clinical utility of automated chemiluminescent antiphospholipid antibody assay. <i>Thrombosis Research</i> , 2015, 136, 1033-1039.	1.7	10
111	Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 125-131.	2.5	12
112	Oral Direct Anticoagulants in Thrombosis Management in Anti-Phospholipid Syndrome: Unanswered Questions. <i>Journal of Hematology & Thromboembolic Diseases</i> , 2015, 03, .	0.1	0
113	Assessing the risk of recurrent venous thromboembolism – a practical approach. <i>Vascular Health and Risk Management</i> , 2015, 11, 451.	2.3	43
114	Laboratory Methodology Important in the Diagnosis and Prognosis of Antiphospholipid Syndrome. , 2015, , .		1
115	Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management"An Insight into Future Approaches. <i>Journal of Immunology Research</i> , 2015, 2015, 1-20.	2.2	48
116	"New"Antigenic Targets and Methodological Approaches for Refining Laboratory Diagnosis of Antiphospholipid Syndrome. <i>Journal of Immunology Research</i> , 2015, 2015, 1-13.	2.2	42
118	The antiphospholipid syndrome: still an enigma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 53-60.	2.5	43
119	Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response. <i>Thrombosis Research</i> , 2015, 136, 1174-1178.	1.7	28
120	ABO blood group in primary antiphospholipid syndrome: influence in the site of thrombosis?. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 374-378.	2.1	5

#	ARTICLE	IF	CITATIONS
121	Postoperative Risk of Venous Thromboembolism in Rheumatic Disease Patients. <i>Current Rheumatology Reports</i> , 2015, 17, 11.	4.7	5
122	Management of perioperative anti-thrombotic therapy. <i>Anaesthesia</i> , 2015, 70, 58.	3.8	44
123	Antiphospholipid syndrome: antibodies to Domain 1 of Î²2â€¦glycoprotein 1 correctly classify patients at risk. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 782-787.	3.8	113
124	The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2028-2033.	0.9	124
125	Antiphospholipid Syndrome: An Important Differential Diagnosis for Culture-negative Endocarditis. <i>American Journal of Medicine</i> , 2015, 128, 250-253.	1.5	4
127	Antibodies to Domain 4/5 (Dm4/5) of Î²2-Glycoprotein 1 (Î²2GP1) in different antiphospholipid (aPL) antibody profiles. <i>Thrombosis Research</i> , 2015, 136, 161-163.	1.7	42
128	Systemic lupus erythematosus and thrombosis. <i>Thrombosis Journal</i> , 2015, 13, 16.	2.1	56
129	The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases. <i>Thrombosis Research</i> , 2015, 135, 1035-1036.	1.7	46
130	Difficult Clinical Situations in the Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2015, 17, 29.	4.7	18
132	Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up. <i>Arthritis Research and Therapy</i> , 2015, 17, 109.	3.5	40
133	THROMBOPHILIC RISK FACTORS ARE UNCOMMON IN YOUNG PATIENTS WITH RETINAL VEIN OCCLUSION. <i>Retina</i> , 2015, 35, 715-719.	1.7	12
134	Frequency of vascular and pregnancy morbidity in patients with low vs. moderate-to-high titers of antiphospholipid antibodies. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 261-266.	1.0	22
135	Associations of Antiphospholipid Antibodies With Splanchnic Vein Thrombosis. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock, 10 Tf 50</i>	1.0	42
136	Antiphospholipid syndrome: an update. <i>European Journal of Clinical Investigation</i> , 2015, 45, 653-662.	3.4	37
137	Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome. <i>Annals of Hematology</i> , 2015, 94, 1291-1299.	1.8	26
138	The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome. <i>Thrombosis Research</i> , 2015, 136, 883-886.	1.7	15
139	The emerging role of multiple antiphospholipid antibodies positivity in patients with antiphospholipid syndrome. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1255-1263.	3.0	10
140	The global anti-phospholipid syndrome score in primary APS. <i>Rheumatology</i> , 2015, 54, 134-138.	1.9	87

#	ARTICLE	IF	CITATIONS
141	Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. <i>Thrombosis Research</i> , 2015, 135, 46-49.	1.7	70
143	The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. <i>European Journal of Rheumatology</i> , 2016, 3, 75-84.	0.6	141
144	Recent advances in understanding antiphospholipid syndrome. <i>F1000Research</i> , 2016, 5, 2908.	1.6	12
145	Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis. <i>PLoS ONE</i> , 2016, 11, e0158757.	2.5	25
146	Hypercoagulability in Kidney Transplant Recipients. <i>Transplantation</i> , 2016, 100, 719-726.	1.0	40
147	Treatment of catastrophic antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2016, 28, 218-227.	4.3	82
148	IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1530-1548.	3.8	84
149	Role of anti-β ₂ glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1779-1787.	3.8	72
150	Prevention of thrombosis in antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 707-713.	2.5	17
151	Evaluation of the diagnostic potential of antibodies to beta ₂ -glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome. <i>Scientific Reports</i> , 2016, 6, 23839.	3.3	23
152	Antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 133-148.	3.3	48
153	Autoantibodies and Biomarkers: Diagnostic Aspects. <i>Rare Diseases of the Immune System</i> , 2016, , 47-59.	0.1	0
154	Current status and future prospects for the treatment of antiphospholipid syndrome. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 927-935.	3.0	8
155	Rivaroxaban to treat thrombotic antiphospholipid syndrome. <i>Lancet Haematology</i> , 2016, 3, e403-e404.	4.6	5
156	Clinical implications of the detection of antibodies directed against domain 1 of β ₂ -glycoprotein 1 in thrombotic antiphospholipid syndrome. <i>Thrombosis Research</i> , 2016, 148, 32-37.	1.7	5
157	APS - Diagnostics and challenges for the future. <i>Autoimmunity Reviews</i> , 2016, 15, 1031-1033.	5.8	29
158	Laboratory testing for antiphospholipid syndrome. <i>International Journal of Laboratory Hematology</i> , 2016, 38, 27-31.	1.3	22
159	Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. <i>Lancet Haematology</i> , 2016, 3, e426-e436.	4.6	322

#	ARTICLE	IF	CITATIONS
160	Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2561-2562.	3.8	1
161	What is known about pediatric antiphospholipid syndrome?. <i>Expert Review of Hematology</i> , 2016, 9, 977-985.	2.2	15
162	Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. <i>Clinical and Molecular Allergy</i> , 2016, 14, 6.	1.8	37
164	Antiphospholipid syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 557-562.	1.0	1
166	The challenges of lupus anticoagulants. <i>Expert Review of Hematology</i> , 2016, 9, 389-400.	2.2	31
167	Patients with antiphospholipid syndrome and thrombotic recurrences: A real world observation (the Tj ETQq1 1 0.784314 rgBT /Overlo	1.6	40
168	Signs of impaired immunoregulation and enhanced effector T-cell responses in the primary antiphospholipid syndrome. <i>Lupus</i> , 2016, 25, 389-398.	1.6	14
169	Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study. <i>Rheumatology</i> , 2016, 55, 817-825.	1.9	9
170	Delineating the deranged immune system in the antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2016, 15, 50-60.	5.8	56
171	Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: a case series and a review: Table A1. <i>Journal of Clinical Pathology</i> , 2016, 69, 337-343.	2.0	13
172	Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. <i>Lupus</i> , 2016, 25, 301-306.	1.6	75
173	The antiphospholipid syndrome: from pathophysiology to treatment. <i>Clinical and Experimental Medicine</i> , 2017, 17, 257-267.	3.6	84
174	Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndrome. <i>Clinical Rheumatology</i> , 2017, 36, 407-412.	2.2	14
175	Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome. <i>Internal and Emergency Medicine</i> , 2017, 12, 1-7.	2.0	28
176	Clinical characteristics and laboratory findings of 252 Chinese patients with anti-phospholipid syndrome: comparison with Euro-Phospholipid cohort. <i>Clinical Rheumatology</i> , 2017, 36, 599-608.	2.2	16
177	Laboratory Markers With Clinical Significance in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 47-69.	0.1	0
178	Primary Prophylaxis in Patients With Positive Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 221-229.	0.1	0
179	Prognosis in Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 281-294.	0.1	0

#	ARTICLE	IF	CITATIONS
180	Clinical significance of anti-domain 1 Î²2-glycoprotein I antibodies in antiphospholipid syndrome. <i>Thrombosis Research</i> , 2017, 153, 90-94.	1.7	37
181	Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibodyâ€positive patients with adverse clinical outcomes. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1412-1421.	3.8	12
182	Plasma Antiphospholipid Antibodies Effects on Activated Partial Thromboplastin Time Assays. <i>American Journal of the Medical Sciences</i> , 2017, 354, 22-26.	1.1	3
183	Antiphospholipid Syndrome. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2317-2330.	2.8	109
185	Antiphospholipid syndrome: an update for clinicians and scientists. <i>Current Opinion in Rheumatology</i> , 2017, 29, 458-466.	4.3	18
186	Pathogenesis and management of antiphospholipid syndrome. <i>British Journal of Haematology</i> , 2017, 178, 181-195.	2.5	80
187	Independent validation of the adjusted GAPSS: Role of thrombotic risk assessment in the real-life setting. <i>Lupus</i> , 2017, 26, 1328-1332.	1.6	31
188	Cessation of oral anticoagulants in antiphospholipid syndrome. <i>Lupus</i> , 2017, 26, 1291-1296.	1.6	26
189	Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?. <i>Lupus</i> , 2017, 26, 1297-1303.	1.6	24
190	Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. <i>The Cochrane Library</i> , 2017, 10, CD012169.	2.8	19
191	Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's. <i>Autoimmunity Reviews</i> , 2017, 16, 1103-1108.	5.8	14
192	Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers. <i>Current Rheumatology Reports</i> , 2017, 19, 43.	4.7	11
193	The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome. <i>American Journal of Hematology</i> , 2017, 92, 1163-1169.	4.1	11
194	Diagnosis and management of the antiphospholipid syndrome. <i>Blood Reviews</i> , 2017, 31, 406-417.	5.7	120
195	Novel enzyme immunoassay system for simultaneous detection of six subclasses of antiphospholipid antibodies for differential diagnosis of antiphospholipid syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 316-322.	1.0	4
197	Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 890-898.	2.3	49
198	The antiphospholipid syndrome in patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2017, 76, 10-20.	6.5	146
199	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. <i>Immunologic Research</i> , 2017, 65, 17-24.	2.9	97

#	ARTICLE	IF	CITATIONS
200	Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. <i>Lupus</i> , 2017, 26, 163-169.	1.6	53
201	Direct oral anticoagulants in hypercoagulable states. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 79-85.	2.1	28
202	Risk factors detection in chronic thromboembolic pulmonary hypertension, a tool for risk quantification?. <i>Bratislava Medical Journal</i> , 2017, 117, 577-582.	0.8	7
203	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. <i>Blood</i> , 2018, 131, 2151-2160.	1.4	62
204	Reduced plasma fibrin clot permeability is associated with recurrent thromboembolic events in patients with antiphospholipid syndrome. <i>Rheumatology</i> , 2018, 57, 1340-1349.	1.9	11
205	Antiphospholipid Antibody Syndrome. , 2018, , 99-111.		0
206	Use of direct oral anticoagulants in antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1028-1039.	3.8	42
207	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. <i>Journal of Autoimmunity</i> , 2018, 90, 1-27.	6.5	60
208	Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 809-813.	3.8	194
210	Antiphospholipid syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 17103.	30.5	233
211	Treatment failure of direct oral anticoagulants in anti-phospholipid syndrome. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 427-428.	1.1	2
213	Direct Oral Anticoagulants and the Paradigm Shift in the Management of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 261-266.	2.7	13
214	Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. <i>Haematologica</i> , 2018, 103, e315-e317.	3.5	34
215	Lupus anticoagulant testing using two parallel methods detects additional cases and predicts persistent positivity. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1289-1296.	2.3	10
216	Laboratory Diagnostics of Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 439-444.	2.7	23
217	Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 427-438.	2.7	13
218	Management of Thrombotic Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 419-426.	2.7	26
220	Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study. <i>Lupus</i> , 2018, 27, 357-364.	1.6	14

#	ARTICLE	IF	CITATIONS
221	The Significance of Antibodies against Domain I of Beta-2 Glycoprotein I in Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 458-465.	2.7	12
222	Direct Oral Anticoagulant Use in Atypical Thrombosis-Related Conditions. <i>Annals of Pharmacotherapy</i> , 2018, 52, 185-197.	1.9	3
223	The Lupus Anticoagulant Paradox. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 445-452.	2.7	33
224	Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study. <i>Rheumatology International</i> , 2018, 38, 229-238.	3.0	2
225	Anticoagulating patients with high-risk acquired thrombophilias. <i>Blood</i> , 2018, 132, 2219-2229.	1.4	13
226	Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns. <i>Thrombosis Research</i> , 2018, 172, 172-178.	1.7	49
227	Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria. <i>Frontiers in Immunology</i> , 2018, 9, 2971.	4.8	65
228	Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 2644.	4.8	16
229	Antiphospholipid Syndrome With Isolated Isotype M Anticardiolipin and/or Anti-B2GPI Antibody Is Associated With Stroke. <i>Stroke</i> , 2018, 49, 2770-2772.	2.0	13
230	Use of factor Xa inhibitors in antiphospholipid antibodies syndrome: A series of seven cases. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2018, 25, 16-21.	0.0	0
231	The clinical value of assays detecting antibodies against domain I of Î²2-glycoprotein I in the antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1210-1218.	5.8	27
232	Genetics of Hypercoagulable and Hypocoagulable States. <i>Neurosurgery Clinics of North America</i> , 2018, 29, 493-501.	1.7	7
233	Utility of current thrombophilia screening in young patients with stroke and TIA. <i>Stroke and Vascular Neurology</i> , 2018, 3, 231-236.	3.3	17
234	Anticoagulating patients with high-risk acquired thrombophilias. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 439-449.	2.5	5
235	Diagnosis and Management of the Antiphospholipid Syndrome. <i>New England Journal of Medicine</i> , 2018, 378, 2010-2021.	27.0	503
236	Clinical value of anti-domain I-Î²2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study. <i>Clinica Chimica Acta</i> , 2018, 485, 74-78.	1.1	13
237	Identification of high thrombotic risk triple-Îµpositive antiphospholipid syndrome patients is dependent on anti-Îµcardiolipin and anti-Î²2glycoprotein I antibody detection assays. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2016-2023.	3.8	51
238	Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?. <i>Vascular Medicine</i> , 2018, 23, 388-399.	1.5	24

#	ARTICLE	IF	CITATIONS
239	Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 969.	4.8	47
240	Laboratory criteria for antiphospholipid syndrome: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2117-2119.	3.8	14
241	Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective. <i>Thrombosis Research</i> , 2018, 169, 35-40.	1.7	31
242	Nonbacterial thrombotic endocarditis in a patient with primary antiphospholipid syndrome. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy024.	0.4	6
243	Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report. <i>Journal of Autoimmunity</i> , 2018, 93, 124-130.	6.5	26
244	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. <i>Blood</i> , 2018, 132, 1365-1371.	1.4	573
245	Perioperative medical management for patients with RA, SPA, and SLE undergoing total hip and total knee replacement: a narrative review. <i>BMC Rheumatology</i> , 2018, 2, 2.	1.6	20
246	Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. <i>Autoimmunity Reviews</i> , 2018, 17, 1011-1021.	5.8	125
247	Antibodies against TFPI and protein C are associated with a severe thrombotic phenotype in patients with and without antiphospholipid syndrome. <i>Thrombosis Research</i> , 2018, 170, 60-68.	1.7	7
250	Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension: A Well-Defined Subgroup of Patients. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1403-1408.	3.4	28
251	Clinical and laboratory practice for lupus anticoagulant testing: An International Society of Thrombosis and Haemostasis Scientific and Standardization Committee survey. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1715-1732.	3.8	32
252	Can we use NOACS in APS?. <i>Autoimmunity Reviews</i> , 2019, 18, 102408.	5.8	8
253	IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients. <i>Frontiers in Medicine</i> , 2019, 6, 211.	2.6	5
254	Acute Systemic Lupus Erythematosus and Antiphospholipid Syndrome With Cardiac Complications. <i>JACC: Case Reports</i> , 2019, 1, 240-242.	0.6	1
255	Therapeutic apheresis during pregnancy: A single center experience. <i>Transfusion and Apheresis Science</i> , 2019, 58, 652-658.	1.0	23
256	Stratifying management of rheumatic disease for pregnancy and breastfeeding. <i>Nature Reviews Rheumatology</i> , 2019, 15, 391-402.	8.0	33
257	Lung Disease in Antiphospholipid Syndrome. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 278-294.	2.1	10
258	Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>RMD Open</i> , 2019, 5, e000924.	3.8	52

#	ARTICLE	IF	CITATIONS
259	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468.	3.4	79
260	New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches. <i>Frontiers in Immunology</i> , 2019, 10, 764.	4.8	30
261	Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL). <i>Frontiers in Immunology</i> , 2019, 10, 885.	4.8	20
262	Platelet Activation by Antiphospholipid Antibodies Depends on Epitope Specificity and is Prevented by mTOR Inhibitors. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1147-1153.	3.4	22
263	Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab. <i>BMJ Case Reports</i> , 2019, 12, e224636.	0.5	2
264	Thrombotic risk factors in patients with antiphospholipid syndrome: a single center experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 233-239.	2.1	10
265	Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: A systematic review and meta-analysis: Comment. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1006-1007.	3.8	1
266	IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. <i>Thrombosis Research</i> , 2019, 177, 157-160.	1.7	30
267	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.9	1,265
268	Thrombophilia, risk factors and prevention. <i>Expert Review of Hematology</i> , 2019, 12, 147-158.	2.2	54
270	Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome. <i>Annals of Internal Medicine</i> , 2019, 171, 685.	3.9	203
271	SP0176...PATHOGENIC ANTIBODIES IN PHOSPHOLIPID SYNDROM. , 2019, , .		0
272	SP0174...ADVANCES IN THE DETECTION OF PATHOGENIC AUTOANTIBODIES IN SLE. , 2019, , .		0
273	SP0175...POST-TRANSLATIONAL MODIFICATIONS OF ANTIBODIES: WHERE THERE'S SMOKE THERE'S FIRE. , 2019, , .		0
274	Laboratory Diagnostics in Thrombophilia. <i>Hamostaseologie</i> , 2019, 39, 049-061.	1.9	26
275	Challenges in Treating Extensive Deep Vein Thrombosis with Severe Thrombocytopenia in Patients with Antiphospholipid Syndrome—A Follow-up of 2 Years. <i>International Journal of Angiology</i> , 2024, 33, 066-069.	0.6	0
276	An Approach to Retiform Purpura for the Inpatient Dermatologist. <i>Current Dermatology Reports</i> , 2019, 8, 245-257.	2.1	1
277	Clinical and immunological features of antiphospholipid syndrome in the elderly: a retrospective national multicentre study. <i>Rheumatology</i> , 2019, 58, 1006-1010.	1.9	15

#	ARTICLE	IF	CITATIONS
278	Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , 2019, 14, 521-527.	2.0	25
279	Antiphospholipid antibodies associated with nodal marginal zone lymphoma and its progression to diffuse large B-cell lymphoma—a case report. <i>Pathology Research and Practice</i> , 2019, 215, 222-228.	2.3	3
280	Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study. <i>Clinical Rheumatology</i> , 2019, 38, 885-893.	2.2	3
281	Thrombophilia. , 2019, , 242-265.		2
283	Recomendaciones de la Sociedad Española de Reumatología sobre síndrome antifosfolípido primario. Parte I: Diagnóstico, evaluación y tratamiento. <i>Reumatología Clínica</i> , 2020, 16, 71-86.	0.5	10
284	The (non)sense of detecting anti-cardiolipin and anti-β ₂ glycoprotein I IgM antibodies in the antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 169-179.	3.8	50
285	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. <i>Blood Reviews</i> , 2020, 39, 100610.	5.7	85
286	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. <i>Rheumatology</i> , 2020, 59, 146-152.	1.9	14
287	Lupus anticoagulant assay cutoffs vary between reagents even when derived from a common set of normal donor plasmas. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 439-444.	3.8	13
288	Antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101463.	3.3	92
289	Use of direct oral anticoagulants in antiphospholipid syndrome: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 259-261.	3.8	5
290	Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 9-12.	2.3	13
291	Recommendations of the Spanish Rheumatology Society for primary antiphospholipid syndrome. Part I: Diagnosis, evaluation and treatment. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 71-86.	0.3	0
292	Managing pregnancy-associated clinical emergencies in systemic lupus erythematosus: a case-based approach. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 5-22.	3.0	3
293	Detection of anti-domain I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: A multicenter multiplatform study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 463-478.	3.8	20
294	Antiphospholipid Syndrome: Therapeutic Challenges. <i>American Journal of Therapeutics</i> , 2020, 27, e328-e330.	0.9	0
295	Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. <i>The Cochrane Library</i> , 2020, 10, CD012169.	2.8	18
296	Loss of antiphospholipid antibody positivity post-thrombosis in SLE. <i>Lupus Science and Medicine</i> , 2020, 7, e000423.	2.7	12

#	ARTICLE	IF	CITATIONS
297	Characteristics of Patients With Antiphospholipid Antibody Positivity in the <scp>APS ACTION</scp> International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2022, 74, 324-335.	3.4	39
298	Coagulopathy in COVID-19: Focus on vascular thrombotic events. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 146, 32-40.	1.9	49
299	Late-onset of primary antiphospholipid syndrome: a case report. <i>Acta Neurologica Belgica</i> , 2021, 121, 1375-1376.	1.1	0
300	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020, 29, 1353-1363.	1.6	28
301	Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Lancet Haematology</i> , 2020, 7, e613-e623.	4.6	6
303	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2828-2839.	3.8	211
305	Venous Thromboembolic Events in African American Lupus Patients are Less Likely Associated with Antiphospholipid Antibodies Compared to Caucasians. <i>Arthritis Care and Research</i> , 2020, , .	3.4	3
306	The assessment of patients with the antiphospholipid antibody syndrome: where are we now?. <i>Rheumatology</i> , 2020, 59, 1489-1494.	1.9	7
307	Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2274-2286.	3.8	24
308	Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: A meta-analysis.. <i>European Journal of Internal Medicine</i> , 2020, 79, 43-50.	2.2	16
309	Management of antiphospholipid syndrome. <i>Clinical Rheumatology</i> , 2020, 39, 2111-2114.	2.2	5
310	Microvascular thrombosis: experimental and clinical implications. <i>Translational Research</i> , 2020, 225, 105-130.	5.0	62
311	Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1846-1848.	3.8	27
312	Thrombin Generation in a patient with Triple Positive Antiphospholipid Syndrome Treated with Three Different Anticoagulants. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102815.	1.0	4
313	Testing for antiphospholipid antibodies: Advances and best practices. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 49-58.	1.3	22
314	How to Interpret Antiphospholipid Laboratory Tests. <i>Current Rheumatology Reports</i> , 2020, 22, 38.	4.7	25
315	Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. <i>Haematologica</i> , 2020, 105, 562-572.	3.5	81
316	Diagnostic biologique du syndrome des antiphospholipides. <i>Revue Francophone Des Laboratoires</i> , 2020, 2020, 34-41.	0.0	0

#	ARTICLE	IF	CITATIONS
317	Antiphospholipid antibodies in patients with COVID-19: A relevant observation?. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2191-2201.	3.8	143
318	What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?. <i>British Journal of Haematology</i> , 2020, 189, 216-227.	2.5	14
319	Tetra positive thrombotic antiphospholipid syndrome: Major contribution of anti-phosphatidylserine/prothrombin antibodies to lupus anticoagulant activity. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1124-1132.	3.8	51
320	Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review. <i>European Journal of Haematology</i> , 2020, 104, 519-525.	2.2	15
321	Treatment of Vascular Thrombosis in Antiphospholipid Syndrome: An Update. <i>Hamostaseologie</i> , 2020, 40, 031-037.	1.9	8
322	Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (<i>Br. J. Haematol</i> 2012; 157: 47-58): use of direct acting oral anticoagulants. <i>British Journal of Haematology</i> , 2020, 189, 212-215.	2.5	53
323	Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus. <i>Lupus</i> , 2020, 29, 256-262.	1.6	19
324	The antiphospholipid syndrome – often overlooked cause of vascular occlusions?. <i>Journal of Internal Medicine</i> , 2020, 287, 349-372.	6.0	27
325	Managing thromboembolic risk in patients with hereditary and acquired thrombophilias. <i>Blood</i> , 2020, 135, 344-350.	1.4	19
326	A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 9-18.	5.2	56
327	Dorsolateral medullary infarction during skin infection by <i>Stenotrophomonas maltophilia</i> in a patient with triple antiphospholipid antibody positivity: a case-based review. <i>Clinical Rheumatology</i> , 2021, 40, 2965-2971.	2.2	2
328	Distinguishing aortic valve thrombus from Libman-Sacks endocarditis in antiphospholipid syndrome: imaging and management. <i>Future Cardiology</i> , 2021, 17, 101-111.	1.2	0
329	Neutrophil subpopulations and their activation potential in patients with antiphospholipid syndrome and healthy individuals. <i>Rheumatology</i> , 2021, 60, 1687-1699.	1.9	15
330	Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management. <i>Thrombosis Research</i> , 2021, 198, 213-221.	1.7	39
331	Insight into the hypercoagulable state of high-risk thrombotic APS patients: Contribution of a ² GPI and aPS/PT antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 805-813.	3.8	15
332	Intensity of immune/clotting assays relate to multiple antiphospholipid antibody positivity in thrombotic primary antiphospholipid syndrome. <i>International Journal of Hematology</i> , 2021, 113, 183-189.	1.6	2
333	Direct Oral Anticoagulants in Select Patients With Hypercoagulable Disorders. <i>Annals of Pharmacotherapy</i> , 2021, 55, 891-901.	1.9	7
334	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 531-535.	3.8	40

#	ARTICLE	IF	CITATIONS
335	Morbidity and mortality in antiphospholipid syndrome based on cluster analysis: a 10-year longitudinal cohort study. <i>Rheumatology</i> , 2021, 60, 1331-1337.	1.9	17
336	Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 607-616.	3.8	45
337	How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Blood</i> , 2021, 137, 299-309.	1.4	15
338	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021, 48, 541-547.	2.0	19
339	Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients. <i>Rheumatology</i> , 2021, 60, 1106-1113.	1.9	18
341	Thrombotic risk in antiphospholipidic syndrome: From hypothesis to current evidence (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 287.	1.8	0
342	The Complex Relationship between C4b-Binding Protein, Warfarin, and Antiphospholipid Antibodies. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1299-1309.	3.4	3
343	A 56-Year-Old Woman with Recurrent Strokes: A Clear Case with a Therapeutic Dilemma. <i>Case Reports in Neurology</i> , 2021, 13, 100-107.	0.7	0
344	Early Initiation of Anticoagulation Improves the Long-Term Prognosis in Patients With Antiphospholipid Syndrome Associated Portal Vein Thrombosis. <i>Frontiers in Medicine</i> , 2021, 8, 630660.	2.6	1
345	Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study. <i>Frontiers in Medicine</i> , 2021, 8, 621590.	2.6	1
346	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 37-45.	3.1	5
347	Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review. <i>Biomedicines</i> , 2021, 9, 166.	3.2	18
348	Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding. <i>Scientific Reports</i> , 2021, 11, 4542.	3.3	3
349	Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?. <i>Biomedicines</i> , 2021, 9, 132.	3.2	11
350	Perioperative Management of Rheumatic Disease and Therapies. <i>Medical Clinics of North America</i> , 2021, 105, 273-284.	2.5	4
351	Correlation between activated clotting time monitoring and heparin concentration measurement in a patient with antiphospholipid syndrome during cardiac valve surgery: a case report. <i>JA Clinical Reports</i> , 2021, 7, 24.	0.7	2
352	Systemic and organ-specific immune-related manifestations of COVID-19. <i>Nature Reviews Rheumatology</i> , 2021, 17, 315-332.	8.0	194
353	S�ndrome antifosfol�pido. <i>Medicine</i> , 2021, 13, 1760-1768.	0.0	0

#	ARTICLE	IF	CITATIONS
354	Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 709-723.	2.7	11
355	Imbalance of circulating CTLA4+ follicular helper and follicular regulatory T cells in obstetric antiphospholipid syndrome. <i>Clinical and Experimental Medicine</i> , 2022, 22, 27-36.	3.6	0
356	Improving the clinical accuracy in patients with antiphospholipid antibodies using anti-phosphatidylserine/prothrombin and anti-beta2 glycoprotein I domain and particle-based multi-analyte technology. <i>Thrombosis Research</i> , 2021, 202, 100-103.	1.7	6
357	International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3177-3192.	3.8	20
358	Deciphered coagulation profile to diagnose the antiphospholipid syndrome using artificial intelligence. <i>Thrombosis Research</i> , 2021, 203, 142-151.	1.7	6
359	Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome. <i>Rheumatology</i> , 2022, 61, 1548-1555.	1.9	6
360	Antiphospholipid Antibodies and Heart Failure with Preserved Ejection Fraction. The Multicenter ATHERO-APS Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3180.	2.4	9
361	Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies. <i>Immunologic Research</i> , 2021, 69, 372-377.	2.9	4
362	Coexistent antiphospholipid syndrome and myeloproliferative neoplasm. <i>Lupus</i> , 2021, 30, 1502-1508.	1.6	4
363	Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 648881.	4.8	9
364	Complement and the prothrombotic state. <i>Blood</i> , 2022, 139, 1954-1972.	1.4	15
365	Antiphospholipid Antibody Syndrome Presenting as Subacute Abdominal Pain Due to Portomesenteric Thrombosis. <i>Journal of Digestive Endoscopy</i> , 0, , .	0.2	0
366	Association between adherence to warfarin and thrombotic events in patients with antiphospholipid syndrome in Japan: A claims-based retrospective cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, , .	1.9	0
367	Follicular helper and follicular regulatory T cell subset imbalance is associated with higher activated B cells and abnormal autoantibody production in primary anti-phospholipid syndrome patients. <i>Clinical and Experimental Immunology</i> , 2021, 206, 141-152.	2.6	7
368	Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One. <i>Frontiers in Immunology</i> , 2021, 12, 726820.	4.8	21
369	Development of multifocal ischemic stroke after cessation of anticoagulant therapy in a patient with antiphospholipid syndrome. <i>Science and Innovations in Medicine</i> , 2021, 6, 42-45.	0.1	0
370	Changes in hemostatic factors after kidney transplantation. <i>Medicine (United States)</i> , 2021, 100, e27179.	1.0	0
371	Direct-acting oral anticoagulants in antiphospholipid syndrome. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 58, 708-715.	1.0	4

#	ARTICLE	IF	CITATIONS
372	Task Force Report on Antiphospholipid Syndrome Clinical Research. , 2012, , 247-257.		7
373	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338.		19
375	The importance of antiphospholipid syndrome testing in venous thromboembolism after varicose vein surgery. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020, 8, 1097-1101.	1.6	1
376	Antiphospholipid syndrome – an update. <i>Vasa - European Journal of Vascular Medicine</i> , 2018, 47, 451-464.	1.4	58
377	Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1220-1227.	3.4	27
378	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. <i>Rheumatology</i> , 2021, 60, 1114-1124.	1.9	41
379	Detection of multiple annexin autoantibodies in a patient with recurrent miscarriages, fulminant stroke and seronegative antiphospholipid syndrome. <i>Biochemia Medica</i> , 2016, 26, 272-278.	2.7	11
380	Dos and don'ts in diagnosing antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 455-459.	2.5	19
381	Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 447-461.	2.3	31
383	Diagnosis and therapy of antiphospholipid syndrome. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 672-677.	0.4	15
384	Laboratory tests in rheumatology: A rational approach. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 198-210.	1.3	6
385	Phospholipid inhibitors. <i>Hamostaseologie</i> , 2011, 31, 243-250.	1.9	3
386	Comparison of the Therapeutic Effects of Rivaroxaban Versus Warfarin in Antiphospholipid Syndrome: A Systematic Review. <i>Archives of Rheumatology</i> , 2020, 35, 107-116.	0.9	4
387	Evaluation of Frequency, Clinical Correlation, and Antibodies Confirmation Profile in Patients with Suspected Antiphospholipid Syndrome. <i>TH Open</i> , 2021, 05, e470-e478.	1.4	2
388	Commentary: Managing catastrophic antiphospholipid syndrome – do we have a way out?. <i>JTCVS Techniques</i> , 2021, 10, 278-279.	0.4	0
389	Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study. <i>Joint Bone Spine</i> , 2022, 89, 105297.	1.6	6
390	Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome. , 2012, , 167-179.		1
391	Task Force Report on –Criteria–Antiphospholipid Antibody Tests. , 2012, , 117-132.		0

#	ARTICLE	IF	CITATIONS
393	Que faire en présence d'anticorps antiphospholipides chez un malade lupique sans passage thrombotique ni obstétrical ?. , 2013, , 99-102.		0
397	Systemic Thromboembolism in Pregnancy: Cerebrovascular Disease. , 2015, , 105-124.		0
398	Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events?. Cureus, 2016, 8, e765.	0.5	7
399	Antiphospholipid Antibody Syndrome in Childhood. , 2017, , 377-392.		0
400	Definition and Epidemiology of Antiphospholipid Syndrome. , 2017, , 147-169.		1
401	Peri-operative care of patients with anticoagulation therapy. Intervencni A Akutni Kardiologie, 2017, 16, 18-22.	0.0	0
405	According to the 2019 updated European League Against Rheumatism (EULAR) recommendations for the treatment of systemic lupus erythematosus: debatable issues and comments. Nauchno-Prakticheskaya Revmatologiya, 2019, 57, 496-510.	1.0	3
406	Pulmonary involvement in antiphospholipid syndrome. , 2019, , 124-139.		0
407	Anticoagulation in Autoimmune Rheumatic Diseases. , 2020, , 159-179.		1
408	Practical approaches to laboratory assessment of risk of recurrent thrombosis in antiphospholipid syndrome. Medical Alphabet, 2020, 4, 16-22.	0.2	1
409	Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome. Journal of Translational Autoimmunity, 2021, 4, 100134.	4.0	21
410	Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?. TH Open, 2020, 04, e446-e456.	1.4	11
411	Trombofilia y trombosis. Medicine, 2020, 13, 1259-1266.	0.0	0
412	A new pro-thrombotic mechanism of neutrophil extracellular traps in antiphospholipid syndrome: impact on activated protein C resistance. Rheumatology, 2022, 61, 2993-2998.	1.9	14
413	RESPIRATORY SYSTEM DISORDERS IN ANTIPHOSPHOLIPID SYNDROME (CLINICAL CASE). , 2021, 78, 181-184.		0
414	Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies™ types and titers™ cross-sectional study of Serbian cohort. Clinical Rheumatology, 2022, , 1.	2.2	3
415	Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study. Arthritis Research and Therapy, 2022, 24, 33.	3.5	9
416	Clinical Management of Thrombotic Antiphospholipid Syndrome. Journal of Clinical Medicine, 2022, 11, 735.	2.4	11

#	ARTICLE	IF	CITATIONS
417	Severe thrombotic events associated with pre-procedural interruption of anticoagulation in systemic lupus erythematosus with secondary antiphospholipid syndrome: Cases and literature review. <i>Lupus</i> , 2022, 31, 261-267.	1.6	2
418	Investigation of the relation between the type and titer of antiphospholipid antibodies and the clinical manifestations of antiphospholipid syndrome. <i>Srpski Medicinski Åesopis Lekarske Komore</i> , 2022, 3, 35-44.	0.1	0
419	Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS). <i>Thrombosis and Haemostasis</i> , 2022, 122, 1612-1620.	3.4	0
420	When Is It Preferable to Use Warfarin?. , 2022, 1, .		0
421	Characterization of recurrent thrombosis in pediatric antiphospholipid syndrome. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	2
422	Perioperative Management of Rheumatic Disease and Therapies. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 455-466.	1.9	1
423	Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndromeâ€”Multicenter, Real-Life Long-Term Follow-Up. <i>Frontiers in Immunology</i> , 2022, 13, 843718.	4.8	8
424	Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances. <i>Journal of Clinical Medicine</i> , 2022, 11, 2164.	2.4	18
425	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2022, 13, 842923.	4.8	0
426	Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey. <i>Rheumatology</i> , 2022, 61, S1136-S1142.	1.9	13
427	Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome. <i>Frontiers in Pharmacology</i> , 2022, 13, 824775.	3.5	4
439	Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study. <i>Journal of Autoimmunity</i> , 2022, 129, 102832.	6.5	3
440	Introductory Chapter: Antiphospholipid Antibodies - A Laboratory Criterion for the Antiphospholipid Syndrome, but Also Bystanders in Infections, Cancer, and Other Conditions. , 0, , .		0
441	Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome. <i>Thrombosis Research</i> , 2022, 214, 132-137.	1.7	13
443	Assessment of antiphospholipid antibodies profiles based on severity of COVID-19 pneumonia. <i>Pan African Medical Journal</i> , 0, 42, .	0.8	2
444	Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2136-2150.	3.8	18
445	Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	12
446	Antiâ€phosphatidylserine prothrombin antibodies as a predictor of the lupus anticoagulant in an allâ€omer population. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2070-2074.	3.8	9

#	ARTICLE	IF	CITATIONS
448	Solid Phase Assays for Antiphospholipid Antibodies. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 661-671.	2.7	11
449	Antiphospholipid Syndrome in Patients with Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 833-839.	2.7	3
450	Real-world evidence of lupus anticoagulant testing: simultaneous positivity of diluted Russell's viper venom time and silica clotting time increases thrombotic risk prediction. <i>Journal of Thrombosis and Thrombolysis</i> , 0, , .	2.1	0
451	Antibodies to domain I ² -glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 353-359.	1.0	1
452	Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8973.	4.1	2
453	Platelet- and endothelial-derived microparticles in the context of different antiphospholipid antibody profiles. <i>Lupus</i> , 2022, 31, 1328-1334.	1.6	5
454	Predictive value of the adjusted Global Anti-Phospholipid Syndrome Score on clinical recurrence in APS patients: a longitudinal study. <i>Rheumatology</i> , 2023, 62, 1576-1585.	1.9	3
455	Antiphospholipid syndrome: Reversal of antiphosphatidylserine/prothrombin-induced activated protein C resistance. <i>Thrombosis Research</i> , 2022, 218, 17-23.	1.7	5
456	Thrombin generation assay and lupus anticoagulant synergically distinguish populations of patients with antiphospholipid antibodies. <i>Journal of Clinical Pathology</i> , 2023, 76, 839-846.	2.0	3
457	The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome. <i>Lupus</i> , 0, , 096120332211221.	1.6	1
458	Efficacy and Safety of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis. <i>Cureus</i> , 2022, , .	0.5	1
459	A review of laboratory considerations in thrombophilia testing. <i>Pathology</i> , 2022, 54, 835-841.	0.6	2
460	Emerging Therapies in Antiphospholipid Syndrome. <i>Transfusion Medicine Reviews</i> , 2022, 36, 195-203.	2.0	1
461	Persistence of antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: A longitudinal study from a single centre. <i>Autoimmunity Reviews</i> , 2022, 21, 103208.	5.8	2
462	The adjusted Global Anti-Phospholipid Syndrome Score as predictor of damage accrual measured by Damage Index for APS: a longitudinal study. <i>Rheumatology</i> , 0, , .	1.9	1
464	“How we treat” clinical dilemmas in antiphospholipid syndrome: A case-based approach. <i>European Journal of Internal Medicine</i> , 2022, , .	2.2	0
465	Ocular findings in asymptomatic patients with primary antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 1800-1807.	1.6	2
466	Frequency and Clinical Significance Anti-PS/PT Antibodies in Patients with Antiphospholipid Syndrome—Single Centre Observational Study in the United Kingdom. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 553-557.	2.7	3

#	ARTICLE	IF	CITATIONS
467	Comparison of Point-of-Care PT-INR by Hand-Held Device with Conventional PT-INR Testing in Anti-phospholipid Antibody Syndrome Patients on Oral Anticoagulation. <i>Indian Journal of Hematology and Blood Transfusion</i> , 0, , .	0.6	0
468	Anticoagulant Therapy in Patients with Antiphospholipid Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 6984.	2.4	7
469	Venous thromboembolism in antiphospholipid syndrome. <i>Vnitřní Lekarství</i> , 2022, 68, 493-497.	0.2	0
470	B-Cells and BAFF in Primary Antiphospholipid Syndrome, Targets for Therapy?. <i>Journal of Clinical Medicine</i> , 2023, 12, 18.	2.4	7
471	Incomplete systemic lupus erythematosus: terminology, diagnosis, course and therapy. <i>Klinická Meditsina</i> , 2022, 100, 447-455.	0.1	0
472	Antiphospholipid syndrome, antiphospholipid antibodies, and stroke. <i>International Journal of Stroke</i> , 2023, 18, 383-391.	5.9	7
473	Update on the Diagnosis and Anticoagulant Treatment of the Antiphospholipid Syndrome. <i>European Medical Journal Rheumatology</i> , 0, , 101-111.	0.0	3
474	Whole blood transcriptome identifies interferon-regulated genes as key drivers in thrombotic primary antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2023, 134, 102978.	6.5	6
475	Evolution of Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 295-304.	2.7	4
476	Antiphospholipid antibodies in chronic thromboembolic pulmonary hypertension. <i>European Journal of Internal Medicine</i> , 2023, 111, 1-4.	2.2	2
477	Is there still room for warfarin after the appearance of direct oral anticoagulants?. <i>Atherothrombosis</i> , 2023, 12, 32-42.	0.3	1
478	Impact of antiphospholipid antibodies on thrombotic events in ambulatory cancer patients. <i>PLoS ONE</i> , 2023, 18, e0279450.	2.5	2
479	A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3169.	4.1	32
480	Retrospective cohort study of thromboembolic events in systemic lupus erythematosus with or without secondary antiphospholipid syndrome and their correlation to lupus activity and dyslipidemia. <i>Egyptian Rheumatology and Rehabilitation</i> , 2023, 50, .	0.6	2
481	Demographic, Clinical, and Serological Characteristics of Antiphospholipid Syndrome Patients From the Anticoagulation Clinic of Hospital Universitario San Vicente Fundación, Medellín, Colombia. <i>Cureus</i> , 2023, , .	0.5	0
482	Management of cardiovascular surgery in patients with systemic lupus erythematosus including thromboembolism and multiple organ failure prevention: A retrospective observational study. <i>Medicine (United States)</i> , 2023, 102, e32979.	1.0	0
483	Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. <i>BMJ</i> , The, 0, , e069717.	6.0	33
484	Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study. <i>RMD Open</i> , 2023, 9, e002881.	3.8	3

#	ARTICLE	IF	CITATIONS
485	An Antiphospholipid Antibody Profile as a Biomarker for Thrombophilia in Systemic Lupus Erythematosus. <i>Biomolecules</i> , 2023, 13, 617.	4.0	1
486	Thrombotic Antiphospholipid Syndrome and Direct Oral Anticoagulants: Unmet Needs and Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 736-743.	2.7	2
487	Relevance of non-criteria antiphospholipid antibodies titers among patients with antiphospholipid syndrome and patients with systemic lupus erythematosus. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2023, 19, 197-203.	0.3	0
488	Laboratory Testing for Non-criteria Antiphospholipid Antibodies: Anti-phosphatidylserine/Prothrombin Antibodies (aPS/PT). <i>Methods in Molecular Biology</i> , 2023, , 315-327.	0.9	3
489	Lupus Anticoagulant Testing: Dilute Prothrombin Time (dPT). <i>Methods in Molecular Biology</i> , 2023, , 275-288.	0.9	2
492	Antithrombotic therapy in antiphospholipid syndrome with arterial thrombosis: a systematic review and network meta-analysis. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	1
493	Long-Term Anticoagulation Therapy for Antiphospholipid Syndrome Following Unsuccessful Arterial Thrombosis Stent Procedure: A Case Report. <i>Clinical Pediatric Hematology-Oncology</i> , 2023, 30, 36-41.	0.2	0
494	Ocular retinal findings in asymptomatic patients with antiphospholipid syndrome secondary to systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2023, 42, 2105-2114.	2.2	0
495	Direct-acting oral anticoagulants in antiphospholipid syndrome: A systematic review. <i>Medicina ClĀnica (English Edition)</i> , 2023, 161, 65-77.	0.2	0
496	Survey on antiphospholipid syndrome diagnosis and antithrombotic treatment in patients with ischemic stroke, other brain ischemic injury, or arterial thromboembolism in other sites: communication from ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2963-2976.	3.8	2
497	Oligosymptomatic infection by SARS-Cov-2 in catastrophic antiphospholipid syndrome, a singular coincidence: a case report in an Ecuadorian hospital. <i>Hematology, Transfusion and Cell Therapy</i> , 2023, , .	0.2	0
498	Assessing disease activity and damage in antiphospholipid syndrome. <i>Clinical Immunology</i> , 2023, 255, 109727.	3.2	1
499	Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 3539-3546.	3.8	1
500	Analytical dilemmas in lupus anticoagulant detection. <i>Exploration of Immunology</i> , 0, , 300-324.	0.3	0
501	Antiphospholipid Syndrome: State of the Art of Clinical Management. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	2.6	1
502	Anti-Ĥ2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China. <i>Lupus Science and Medicine</i> , 2023, 10, e000924.	2.7	0
503	Comorbid association of obstructive sleep apnea (OSA) and thrombotic primary antiphospholipid syndrome (tPAPS): A more severe phenotype?. <i>Clinical Immunology</i> , 2023, 256, 109781.	3.2	0
504	A review on management of antiphospholipid syndrome in clinical practice. <i>Italian Journal of Medicine</i> , 2023, 17, .	0.3	0

#	ARTICLE	IF	CITATIONS
505	Antiphospholipid Syndrome: Thrombotic and Vascular Complications. <i>Cardiology in Review</i> , 0, , .	1.4	0
506	Clinical features, risk factors, and outcomes of diffuse alveolar hemorrhage in antiphospholipid syndrome: A mixed-method approach combining a multicenter cohort with a systematic literature review. <i>Clinical Immunology</i> , 2023, 256, 109775.	3.2	0
507	Antiphospholipid syndrome and kidney involvement. <i>Kidney and Blood Pressure Research</i> , 0, , .	2.0	0
508	Risk factors and recurrent thrombosis in primary antiphospholipid syndrome. <i>Exploration of Immunology</i> , 0, , 475-489.	0.3	0
509	Antibodies to Domain I Î²2-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>Doklady Biochemistry and Biophysics</i> , 2023, 511, 219-226.	0.9	0
510	Complement biomarkers in the antiphospholipid syndrome â€“ Approaches to quantification and implications for clinical management. <i>Clinical Immunology</i> , 2023, 257, 109828.	3.2	0
511	Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials. <i>Lupus Science and Medicine</i> , 2023, 10, e001018.	2.7	0
512	Risks Following Total Knee Arthroplasty in Patients Who Have Antiphospholipid Syndrome. <i>Journal of Arthroplasty</i> , 2023, , .	3.1	0
513	Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository (â€œRegistryâ€œ). <i>Seminars in Arthritis and Rheumatism</i> , 2024, 65, 152347.	3.4	0
514	Deciphering the clinical significance of longitudinal antiphospholipid antibody titers. <i>Autoimmunity Reviews</i> , 2024, 23, 103510.	5.8	1
515	A Comprehensive Review of Risk Factors and Thrombophilia Evaluation in Venous Thromboembolism. <i>Journal of Clinical Medicine</i> , 2024, 13, 362.	2.4	0
516	A study of recurrent life-threatening thrombosis accompanied with the duplication of the factor IX gene. <i>Thrombosis Journal</i> , 2024, 22, .	2.1	0
517	Should bleeding be a concern in antiphospholipid syndrome?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2024, 8, 102328.	2.3	0
518	Comparison of different algorithms for lupus anticoagulant detection: a single-center experience. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2024, 8, 102333.	2.3	0
519	Taipan snake venom time has high sensitivity for lupus anticoagulants in nonâ€œanticoagulated, triple positive antiphospholipid syndrome patients. <i>International Journal of Laboratory Hematology</i> , 2024, 46, 538-545.	1.3	0
520	Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations. <i>Rheumatology</i> , 2024, 63, S124-S136.	1.9	1
521	The impact of antiphospholipid antibodies/antiphospholipid syndrome on systemic lupus erythematosus. <i>Rheumatology</i> , 2024, 63, S172-S185.	1.9	1
522	Viewpoint: Provoked thrombosis in antiphospholipid syndrome. <i>Rheumatology</i> , 2024, 63, S137-S145.	1.9	1

#	ARTICLE	IF	CITATIONS
523	Viewpoint: Lupus anticoagulant detection and interpretation in antiphospholipid syndrome. <i>Rheumatology</i> , 2024, 63, SI54-SI63.	1.9	1
524	Risk factors for damage accrual in primary antiphospholipid syndrome: A retrospective single-center cohort study. <i>Journal of Autoimmunity</i> , 2024, 144, 103180.	6.5	0
525	Thrombin Generation Assay in Antiphospholipid Antibodies Positive Subjects as a Personalized Thrombotic Risk Assessment: State of the Art and Perspectives. <i>Current Rheumatology Reports</i> , 2024, 26, 178-187.	4.7	0
526	Rare diagnosis of coexistent antiphospholipid syndrome and systemic lupus erythematosus in a male patient with successful management: a case report. <i>Annals of Medicine and Surgery</i> , 2023, 85, 1983-1986.	1.1	0